AI Article Synopsis
Article Abstract
The purpose of this study is to report a case of retinal capillary hemangioma treated with ruthenium-106 brachytherapy combined with intravitreal bevacizumab. A 58-year-old woman presented with blurred vision in her left eye for 15 days. Best-corrected visual acuity (BCVA) was counting fingers at 3 m in her left eye. Examination showed a peripheral endophytic retinal capillary hemangioma, with associated macular edema and diffuse hard exudates in a macular star pattern. B-scan ultrasonography revealed a solid, highly reflective retinal tumor measuring 7.1 × 7.5 mm in basal dimension and 3.5 mm in thickness. The hemangioma and macular edema were treated with ruthenium-106 brachytherapy (500 Gy) followed 1 month later with an intravitreal injection of 1.25 mg (0.05 ml) bevacizumab. After 10 months of follow-up, examination demonstrated involution of the hemangioma, resolution of the macular edema, less hard exudates, and improvement of BCVA to 20/25. Ruthenium-106 brachytherapy combined with intravitreal bevacizumab was associated with significant involution of the choroidal hemangioma with resolution of the macular edema and improvement in visual acuity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10792-011-9513-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ruthenium-106 brachytherapy and central uveal melanoma.
Int Ophthalmol
January 2025
Department of Ophthalmology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane, Dessau, Germany.
Purpose: Uveal melanoma (UM) is the most common primary ocular malignancy. The size and location of the tumor are decisive for brachytherapy with the β-emitting ruthenium-106 (Ru-106) plaque. The treatment of juxtapapillary and juxtafoveolar UM may be challenging because of the proximity or involvement of the macula and optic nerve and high recurrence rates.
View Article and Find Full Text PDFA retrospective study on ruthenium-106 and strontium-90 eye-plaques treatment for retinoblastoma: 16-years clinical experience.
Brachytherapy
January 2025
Ocular Oncology and Radiology Department, S. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russia.
Purpose: To retrospectively evaluate the efficacy of plaque brachytherapy for the treatment of retinoblastoma.
Methods: We retrospectively reviewed the clinical records of 163 patients (186 eyes, 333 tumors) treated with brachytherapy (Ru or Sr plaques) for intraocular retinoblastoma between November 2007 and August 2023.
Results: Complete tumor control was achieved in 273 tumors (82%).
Clinical Features and Initial Management Outcomes of Uveal Melanomas in a Single Tertiary Center in Egypt.
Ocul Oncol Pathol
December 2024
Cairo University Ocular Oncology Service, Department of Ophthalmology, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt.
Article Synopsis
- The study focuses on the demographic, clinical, and management outcomes of patients with uveal melanoma at a tertiary center in Egypt over five years.
- A total of 93 patients were treated, with most tumors being choroidal, and common treatments included brachytherapy and gamma knife radiosurgery, leading to a successful globe salvage rate of 84.62%.
- The conclusion emphasizes the importance of timely referrals and proper assessments to improve treatment success and highlights the need for advanced tumor patients to consider enucleation to lower the risk of metastasis and mortality.
Expert Opinions on Uveal Melanoma: Insights from the 58th Ophthalmic Oncology Group Meeting.
Ocul Oncol Pathol
December 2024
Ophthalmology Department, Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, University of Lausanne, Lausanne, Switzerland.
Introduction: Clear evidence for the best clinical management of uveal melanoma is lacking in some areas. Therefore, reports on expert opinions in the field can be valuable.
Methods: A questionnaire comprising 10 questions was distributed to potential participants of the 58th Ophthalmic Oncology Group Meeting in Stockholm, Sweden, in June 2024.
Ruthenium-106 (Ru) plaque brachytherapy as salvage treatment for retinoblastoma following intravenous chemotherapy.
Brachytherapy
January 2025
The Operation Eyesight Universal Institute for Eye Cancer, L V Prasad Eye Institute, Road no 2, Banjara Hills, Hyderabad, 500034 India.
Purpose: To describe the clinical presentation and treatment outcomes of patients undergoing Ruthenium-106 (Ru) plaque brachytherapy as salvage treatment for retinoblastoma (RB) following intravenous chemotherapy (IVC).
Methods: Retrospective chart review of 44 eyes of 42 patients. The indications for plaque brachytherapy included solid tumor recurrence (n=20; 45%), solid tumor residual (n=16; 36%), new subretinal seeds (n=5; 12%), and new solid tumor (n=3; 7%).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!